Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A...
Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A...
Foxo Technologies Inc. 宣布进行重组和融资交易,并任命 Seamus Lagan 为首席执行官;主要交易包括:Rennova Health 交换约2100万美元的高级担保票据,兑换公司A系列的21000股...
Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A Cumulative Convertible Redeemable Preferred Stock; An Institutional Investor's Additional Funding Of $1M And Exchange Of $2.2M Of Senior Notes
Foxo Technologies Inc. 宣布重组和融资交易,并任命Seamus Lagan为首席执行官;主要交易包括:Rennova Health 交易约2100万的高级担保票据,转换为公司 21000 股 A系列累积可转换可赎回优先股;一位机构投资者额外资助100万和交换220万的高级票据
FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO") announces a series of restructuring and capital raising transactions which will improve the Company's balance sheet, satisfy minimum stockholders' equity requirements of the NYSE American and provide capital for growth and reduce outstanding liabilities. The Company also announces a change in senior leadership.
FOXO Technologies Inc. (纽交所美国: FOXO)("公司"或"FOXO")宣布系列重组和融资交易,这将改善公司的资产负债表,满足纽交所美国的最低股东权益要求,并为增长提供资本、减少未偿债务。公司还宣布高层领导变更。
Key transactions include:
主要交易包括:
- Rennova Health, Inc.'s exchange of approximately $21 million of a Senior Secured Note issued by Rennova Community Health, Inc., the Company's subsidiary, into 21,000 shares of the Company's Series A Cumulative Convertible Redeemable Preferred Stock
- An institutional investor's additional funding of $1.0 million and exchange of $2.2 million of Senior Notes (which includes the $1.0 million of additional funding) into 2,464 shares of the Company's Series A Preferred Stock
- Settlement of certain liabilities owed to KR8, Inc. and the termination of a current license agreement for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
- Settlement of certain liabilities owed to KR8, Inc. and the termination of a current license agreement for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
- Rennova Health, Inc. 交换由Rennova Community Health, Inc.(公司的子公司)发行的约2100万的高级担保票据,转换为公司21000股A系列累积可转换可赎回优先股
- 一位机构投资者额外资助100万,并将220万的高级票据(包括100万的额外资助)转换为公司2,464股A系列优先股
- 解决欠KR8, Inc.的某些债务,以及终止针对公司3,000股新指定的D系列累积可转换可赎回优先股的当前许可证协议
- 解决欠KR8, Inc.的某些债务,以及终止针对公司3,000股新指定的D系列累积可转换可赎回优先股的当前许可证协议
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。